Inhaler Group UK explore the impact of inhaled therapies next March in London

SMi’s 13th annual Asthma & COPD conference returns to London on the 29th and 30th March 2017.

Monica Fletcher OBE, Chief Executive of Education for Health and Chair of the UK Inhaler Group joins this year’s speaker panel for Asthma & COPD 2017. Monica will be speaking on day one of the conference on ‘Maximising the use and impact of inhaled therapies; addressing the true needs of patients and HCPs’, where she will discuss crucial matters surrounding inhalers, such as patient compliance and educating patient and healthcare professionals. She will explore:

•    How do patients and HCPs describe their inhalers?
•    Will technology help or hinder adherence?
•    How can we educate patients and HCPs?

Last year AstraZeneca changed the blue colour of their Duaklir® Genuair® inhaler over concerns about patients mistakenly using this as a reliever inhaler. ‘’The UKIG recommend that blue colouring on inhaler devices should be reserved for “reliever” inhalers and should not be present on “preventer” inhalers, in case this confuses patients who may mistakenly take extra doses during the day or night rather than using their “reliever” inhaler."  *(Source)

Monica praised this change from AstraZeneca; "We are delighted with the proactive response from AstraZeneca to collective concerns about the importance of colour coding inhaler devices and the potential for serious patient safety risks associated with the colour of inhaler devices. By changing the colour of the Duaklir® Genuair® inhaler we believe that greater clarity and patient safety will result.” *(Source)

It is of utmost importance for industry to collaborate to ensure that respiratory medicines are used safely by patients and that adherence to treatment is addressed. Therefore it highlights the need to address so many ongoing issues regarding these two respiratory diseases.

Other sessions which are not to be missed include insightful presentations from: MHRA, GSK, Boehringer Ingelheim, Glenmark Pharmaceuticals, Janssen, Novartis, Teva, AstraZeneca, MedImmune, Mylan, Imperial College of London, Actavis and many more...

Hot topics for the 2017 agenda include: regulatory updates, therapeutic developments, COPD updates, novel approaches to treatment and electronic health monitoring.

Two CPD certified pre-conference workshops will be hosted alongside the conference by Cambridge Consultants and Janssen.

There is currently an early bird offer available; book by 16th of December to save £200 off the conference price. Register at www.asthma-copd.co.uk/biopharmadive  

For sponsorship packages: Contact Alia Malick on +44 (0)20 7827 6168 or email [email protected]-online.co.uk

For delegate enquiries: Contact Ameenah Begum on +44 (0)20 7827 6166 or email 
[email protected]-online.co.uk

For media enquiries, contact Zoe Gale on +44 20 7827 6138 or [email protected]-online.co.uk 

13th annual Asthma & COPD
29-30 March 2017
London, UK
www.asthma-copd.co.uk/biopharmadive 
Contact e-mail: [email protected]-online.co.uk
Contact tel: +44 (0) 207 827 6166 
#asthmacopdsmi 
*(Source) http://bit.ly/2gpt6ZF

---- END ----
About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk